Genprex To Present At 2018 Disruptive Growth & Healthcare Conference
May 7, 2018
AUSTIN, Texas, May 7, 2018 /PRNewswire/ — Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that Rodney Varner, Chairman and CEO, will present at the 2018 Disruptive Growth & Healthcare Conference to be held in New York City on May 8-9, 2018. The Company is scheduled to present on Tuesday, May 8, 2018 at 1:15 PM EDT.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.
SOURCE Genprex, Inc.